You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLorcaserin
Accession NumberDB04871
TypeSmall Molecule
GroupsApproved
DescriptionLorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.
Structure
Thumb
Synonyms
Lorqess
External Identifiers
  • APD-356
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Belviqtablet10 mg/1oralEisai Inc.2012-06-27Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LorqessNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Lorcaserin hydrochloride
846589-98-8
Thumb
  • InChI Key: ITIHHRMYZPNGRC-QRPNPIFTSA-N
  • Monoisotopic Mass: 231.058154899
  • Average Mass: 232.15
DBSALT000111
Lorcaserin hydrochloride hemihydrate
ThumbNot applicableDBSALT001583
Categories
UNII637E494O0Z
CAS number616202-92-7
WeightAverage: 195.69
Monoisotopic: 195.0814772
Chemical FormulaC11H14ClN
InChI KeyXTTZERNUQAFMOF-QMMMGPOBSA-N
InChI
InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1
IUPAC Name
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
SMILES
C[[email protected]]1CNCCC2=CC=C(Cl)C=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassNot Available
Direct ParentBenzazepines
Alternative Parents
Substituents
  • Benzazepine
  • Azepine
  • Aralkylamine
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Secondary amine
  • Secondary aliphatic amine
  • Azacycle
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Organic nitrogen compound
  • Amine
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.
PharmacodynamicsLorcaserin produced a dose-dependent weight loss over a 12-week period by promoting satiety and decreasing food consumption.
Mechanism of actionAlthough the exact mechanism is unknown, it is believed to involve the selective activation of 5-HT2C receptors in the anorexigenic pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus. This results in decreased food intake and satiety by promoting the release of alpha-melanocortin stimulating hormone, which acts on melanocortin-4 receptors.
Related Articles
AbsorptionLorcaserin has a peak plasma concentration of about 1.5 - 2 hours, but the bioavailability was not determined.
Volume of distribution

The volume of distribution was not determined, but lorcaserin distributes to the central nervous system and cerebrospinal fluid.

Protein bindingLorcaserin hydrochloride has a plasma protein binding of approximately 70%.
Metabolism

Lorcaserin has extensive hepatic metabolism producing inactive compounds. Lorcaserin sulfamate (M1) is the major metabolite circulating in the plasma, and N-carbamoyl glucuronide lorcaserin (M5) is the major metabolite in urine. Other minor metabolites that are both excreted in urine are glucuronide or sulfate conjugates.

SubstrateEnzymesProduct
Lorcaserin
Not Available
Lorcaserin sulfamateDetails
Lorcaserin
Not Available
N-carbamoyl glucuronide lorcaserinDetails
Route of eliminationLorcaserin is eliminated by hepatic metabolism, and the metabolites are eliminated mostly in the urine (92.3%) and some through feces (2.2%).
Half lifeThe plasma half life is approximately 11 hours.
Clearance

The clearance value was not determined.

ToxicityMost common adverse reactions include hypoglycemia (diabetic patients), headache, back pain,fatigue, decrease in lymphocytes,upper respiratory tract infection, and nasopharyngitis. Moreover, the safety and efficacy of coadministration with other weight loss products has not been established, and cardiovascular effects on mortality and morbidity have not been established.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6953787 No2003-04-102023-04-10Us
US7514422 No2003-04-102023-04-10Us
US7977329 No2003-04-102023-04-10Us
US8168624 No2009-04-182029-04-18Us
US8207158 No2003-04-102023-04-10Us
US8273734 No2003-04-102023-04-10Us
US8367657 No2003-04-102023-04-10Us
US8546379 No2003-04-102023-04-10Us
US8575149 No2003-04-102023-04-10Us
US8697686 No2005-12-202025-12-20Us
US8946207 No2004-06-162024-06-16Us
US8980881 No2005-12-202025-12-20Us
US8999970 No2013-02-072033-02-07Us
US9169213 No2012-12-062032-12-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityWater solubility is greater than 400 mg/mL.From FDA label.
Predicted Properties
PropertyValueSource
Water Solubility0.0709 mg/mLALOGPS
logP3ALOGPS
logP2.83ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)10.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity56.65 m3·mol-1ChemAxon
Polarizability21.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jandacek RJ: APD-356 (Arena). Curr Opin Investig Drugs. 2005 Oct;6(10):1051-6.

General References
  1. Halford JC: Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006 Apr;7(4):312-8. [PubMed:16625817 ]
  2. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Dosa PI, Covel JA, Ren A, Webb RR, Beeley NR, Martin M, Morgan M, Espitia S, Saldana HR, Bjenning C, Whelan KT, Grottick AJ, Menzaghi F, Thomsen WJ: Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem. 2008 Jan 24;51(2):305-13. Epub 2007 Dec 21. [PubMed:18095642 ]
External Links
ATC CodesA08AA11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (401 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lorcaserin.
AbirateroneThe serum concentration of Lorcaserin can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Lorcaserin.
AcetophenazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Lorcaserin.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Lorcaserin.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Lorcaserin.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lorcaserin.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Lorcaserin.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Lorcaserin.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Lorcaserin.
AmiodaroneThe metabolism of Lorcaserin can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Amisulpride.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Lorcaserin.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lorcaserin.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Lorcaserin.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lorcaserin.
AmperozideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Amperozide.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Lorcaserin.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Lorcaserin.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Lorcaserin.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Lorcaserin.
AprepitantThe serum concentration of Lorcaserin can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Lorcaserin.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Lorcaserin.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lorcaserin.
ArmodafinilThe metabolism of Lorcaserin can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Artemether can be decreased when combined with Lorcaserin.
AsenapineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Lorcaserin.
AtazanavirThe metabolism of Lorcaserin can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Lorcaserin can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Azaperone.
AzelastineThe metabolism of Azelastine can be decreased when combined with Lorcaserin.
AzithromycinThe metabolism of Lorcaserin can be decreased when combined with Azithromycin.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Lorcaserin.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Lorcaserin.
BepridilThe metabolism of Bepridil can be decreased when combined with Lorcaserin.
BetaxololThe metabolism of Lorcaserin can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Lorcaserin can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Bifeprunox.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Lorcaserin.
BoceprevirThe metabolism of Lorcaserin can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Lorcaserin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Lorcaserin can be decreased when it is combined with Bosentan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Lorcaserin.
BromocriptineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Lorcaserin.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Lorcaserin.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Lorcaserin.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Lorcaserin.
BupropionBupropion may increase the serotonergic activities of Lorcaserin.
BupropionThe metabolism of Bupropion can be decreased when combined with Lorcaserin.
BuspironeThe metabolism of Buspirone can be decreased when combined with Lorcaserin.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lorcaserin.
CabergolineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Cabergoline.
CaffeineThe metabolism of Lorcaserin can be decreased when combined with Caffeine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Lorcaserin.
CarbamazepineThe metabolism of Lorcaserin can be increased when combined with Carbamazepine.
CariprazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Cariprazine.
CarteololThe metabolism of Carteolol can be decreased when combined with Lorcaserin.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Lorcaserin.
CelecoxibThe metabolism of Lorcaserin can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Lorcaserin.
CeritinibThe serum concentration of Lorcaserin can be increased when it is combined with Ceritinib.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Lorcaserin.
ChloramphenicolThe metabolism of Lorcaserin can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Lorcaserin.
ChloroquineThe metabolism of Lorcaserin can be decreased when combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Lorcaserin.
ChlorpromazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Lorcaserin can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Lorcaserin.
CholecalciferolThe metabolism of Lorcaserin can be decreased when combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Lorcaserin.
CimetidineThe metabolism of Lorcaserin can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Lorcaserin can be decreased when combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Lorcaserin.
CitalopramThe metabolism of Lorcaserin can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Lorcaserin can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Lorcaserin can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Lorcaserin.
ClobazamThe metabolism of Lorcaserin can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Lorcaserin can be decreased when combined with Clomipramine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Lorcaserin.
ClopidogrelThe metabolism of Lorcaserin can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Lorcaserin can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Clozapine.
ClozapineThe metabolism of Lorcaserin can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Lorcaserin can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Lorcaserin can be decreased when combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Lorcaserin.
ConivaptanThe serum concentration of Lorcaserin can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Lorcaserin can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Cyamemazine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Lorcaserin.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lorcaserin.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Lorcaserin.
CyclosporineThe metabolism of Lorcaserin can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Lorcaserin can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Lorcaserin can be decreased when it is combined with Dabrafenib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Lorcaserin.
DapiprazoleThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lorcaserin.
DarifenacinThe metabolism of Lorcaserin can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Lorcaserin can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Lorcaserin.
DasatinibThe serum concentration of Lorcaserin can be increased when it is combined with Dasatinib.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Lorcaserin.
DeferasiroxThe serum concentration of Lorcaserin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Lorcaserin can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Lorcaserin can be decreased when combined with Desipramine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Desvenlafaxine.
DexamethasoneThe serum concentration of Lorcaserin can be decreased when it is combined with Dexamethasone.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Lorcaserin.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Lorcaserin.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Lorcaserin.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Lorcaserin.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lorcaserin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Lorcaserin.
DihydroergotamineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Dihydroergotamine.
DihydroergotamineThe metabolism of Lorcaserin can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Lorcaserin can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Lorcaserin can be decreased when combined with Diphenhydramine.
DolasetronDolasetron may increase the serotonergic activities of Lorcaserin.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Lorcaserin.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Lorcaserin.
DonepezilThe metabolism of Donepezil can be decreased when combined with Lorcaserin.
DopamineThe metabolism of Dopamine can be decreased when combined with Lorcaserin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Lorcaserin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Lorcaserin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Lorcaserin.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Lorcaserin.
DoxycyclineThe metabolism of Lorcaserin can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Lorcaserin can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Droperidol.
DuloxetineThe metabolism of Lorcaserin can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Lorcaserin can be decreased when it is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Lorcaserin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lorcaserin.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Lorcaserin.
EncainideThe metabolism of Encainide can be decreased when combined with Lorcaserin.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Lorcaserin.
EnzalutamideThe serum concentration of Lorcaserin can be decreased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Lorcaserin.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergotamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Lorcaserin.
ErythromycinThe metabolism of Lorcaserin can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Lorcaserin.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Lorcaserin.
Eslicarbazepine acetateThe serum concentration of Lorcaserin can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Lorcaserin.
EsomeprazoleThe metabolism of Lorcaserin can be decreased when combined with Esomeprazole.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Lorcaserin.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Lorcaserin.
EtravirineThe serum concentration of Lorcaserin can be decreased when it is combined with Etravirine.
FencamfamineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fencamfamine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lorcaserin.
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Lorcaserin.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Lorcaserin.
FlecainideThe metabolism of Flecainide can be decreased when combined with Lorcaserin.
FluconazoleThe metabolism of Lorcaserin can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Lorcaserin.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Lorcaserin.
FlupentixolThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluspirilene.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Lorcaserin.
FluvoxamineThe metabolism of Lorcaserin can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Lorcaserin.
FosamprenavirThe metabolism of Lorcaserin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Lorcaserin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Lorcaserin can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Lorcaserin.
Fusidic AcidThe serum concentration of Lorcaserin can be increased when it is combined with Fusidic Acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Lorcaserin.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Lorcaserin.
GemfibrozilThe metabolism of Lorcaserin can be decreased when combined with Gemfibrozil.
GranisetronGranisetron may increase the serotonergic activities of Lorcaserin.
GranisetronThe metabolism of Granisetron can be decreased when combined with Lorcaserin.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Lorcaserin.
HaloperidolThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Haloperidol.
HaloperidolThe metabolism of Lorcaserin can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Lorcaserin.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Lorcaserin.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Lorcaserin.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Lorcaserin.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Lorcaserin.
IdelalisibThe serum concentration of Lorcaserin can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Iloperidone.
ImatinibThe metabolism of Lorcaserin can be decreased when combined with Imatinib.
ImipramineThe metabolism of Lorcaserin can be decreased when combined with Imipramine.
IndinavirThe metabolism of Lorcaserin can be decreased when combined with Indinavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Lorcaserin.
IsavuconazoniumThe metabolism of Lorcaserin can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lorcaserin.
IsoniazidThe metabolism of Lorcaserin can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Lorcaserin can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Lorcaserin can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Lorcaserin can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Lorcaserin.
KetoconazoleThe metabolism of Lorcaserin can be decreased when combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Lorcaserin.
LevodopaThe metabolism of Levodopa can be decreased when combined with Lorcaserin.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Lorcaserin.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Lorcaserin.
LidocaineThe metabolism of Lorcaserin can be decreased when combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Lorcaserin.
LisurideThe metabolism of Lisuride can be decreased when combined with Lorcaserin.
LithiumThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Lithium.
LomustineThe metabolism of Lomustine can be decreased when combined with Lorcaserin.
LoperamideThe metabolism of Loperamide can be decreased when combined with Lorcaserin.
LopinavirThe metabolism of Lorcaserin can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Lorcaserin can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Loxapine.
LuliconazoleThe serum concentration of Lorcaserin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Lorcaserin can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Lorcaserin can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Lurasidone.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Lorcaserin.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lorcaserin.
MelperoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Melperone.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Lorcaserin.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Lorcaserin.
MesoridazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Mesoridazine.
MethadoneThe metabolism of Lorcaserin can be decreased when combined with Methadone.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Lorcaserin.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Methotrimeprazine.
MethotrimeprazineThe metabolism of Lorcaserin can be decreased when combined with Methotrimeprazine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Lorcaserin.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Lorcaserin.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Lorcaserin.
MetoclopramideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Metoclopramide.
MetoprololThe metabolism of Lorcaserin can be decreased when combined with Metoprolol.
MexiletineThe metabolism of Lorcaserin can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Lorcaserin.
MifepristoneThe metabolism of Lorcaserin can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Lorcaserin.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Lorcaserin.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Lorcaserin.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lorcaserin.
MitotaneThe serum concentration of Lorcaserin can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Lorcaserin.
ModafinilThe serum concentration of Lorcaserin can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Molindone.
MorphineThe metabolism of Morphine can be decreased when combined with Lorcaserin.
NafcillinThe serum concentration of Lorcaserin can be decreased when it is combined with Nafcillin.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Lorcaserin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Lorcaserin.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Lorcaserin.
NefazodoneThe metabolism of Lorcaserin can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Lorcaserin can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Lorcaserin can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Lorcaserin.
NevirapineThe metabolism of Lorcaserin can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Lorcaserin can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Lorcaserin.
NicotineThe metabolism of Nicotine can be decreased when combined with Lorcaserin.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Lorcaserin.
NilotinibThe metabolism of Lorcaserin can be decreased when combined with Nilotinib.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Lorcaserin.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Lorcaserin.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lorcaserin.
OlanzapineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Olanzapine.
OlaparibThe metabolism of Lorcaserin can be decreased when combined with Olaparib.
OmeprazoleThe metabolism of Lorcaserin can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Lorcaserin.
OsanetantThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Osanetant.
OsimertinibThe serum concentration of Lorcaserin can be increased when it is combined with Osimertinib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Lorcaserin.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Lorcaserin.
PalbociclibThe serum concentration of Lorcaserin can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Lorcaserin.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Lorcaserin.
PanobinostatThe metabolism of Lorcaserin can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Lorcaserin can be decreased when combined with Pantoprazole.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Lorcaserin.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Lorcaserin.
Peginterferon alfa-2bThe serum concentration of Lorcaserin can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Lorcaserin.
PentobarbitalThe metabolism of Lorcaserin can be increased when combined with Pentobarbital.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Lorcaserin.
PerospironeThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Perphenazine.
PethidineThe metabolism of Pethidine can be decreased when combined with Lorcaserin.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lorcaserin.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Lorcaserin.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lorcaserin.
PhenforminThe metabolism of Phenformin can be decreased when combined with Lorcaserin.
PhenobarbitalThe metabolism of Lorcaserin can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Lorcaserin can be increased when combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pimozide.
PindololThe metabolism of Pindolol can be decreased when combined with Lorcaserin.
PipamperoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Lorcaserin.
PipotiazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pipotiazine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Lorcaserin.
PosaconazoleThe metabolism of Lorcaserin can be decreased when combined with Posaconazole.
PrimidoneThe metabolism of Lorcaserin can be increased when combined with Primidone.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Lorcaserin.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Lorcaserin.
ProchlorperazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Prochlorperazine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Lorcaserin.
PromazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Promazine.
PromazineThe metabolism of Lorcaserin can be decreased when combined with Promazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Lorcaserin.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Lorcaserin.
PropafenoneThe serum concentration of Lorcaserin can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Lorcaserin.
PropericiazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Propericiazine.
PropofolThe metabolism of Propofol can be decreased when combined with Lorcaserin.
PropranololThe metabolism of Propranolol can be decreased when combined with Lorcaserin.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Lorcaserin.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lorcaserin.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Lorcaserin.
QuazepamThe serum concentration of Lorcaserin can be increased when it is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Quetiapine.
QuinidineThe metabolism of Lorcaserin can be decreased when combined with Quinidine.
QuinineThe metabolism of Lorcaserin can be decreased when combined with Quinine.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Lorcaserin.
RanolazineThe metabolism of Lorcaserin can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lorcaserin.
RemoxiprideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Remoxipride.
repinotanThe metabolism of repinotan can be decreased when combined with Lorcaserin.
ReserpineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Reserpine.
RifabutinThe metabolism of Lorcaserin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Lorcaserin can be increased when combined with Rifampicin.
RifapentineThe metabolism of Lorcaserin can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Risperidone.
RitonavirThe metabolism of Lorcaserin can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Lorcaserin.
RolapitantThe metabolism of Lorcaserin can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Lorcaserin can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Lorcaserin.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Lorcaserin.
SaquinavirThe metabolism of Lorcaserin can be decreased when combined with Saquinavir.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Lorcaserin.
SertindoleThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sertindole.
SertralineThe metabolism of Lorcaserin can be decreased when combined with Sertraline.
SildenafilThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sildenafil.
SildenafilThe metabolism of Lorcaserin can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Lorcaserin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Lorcaserin can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Lorcaserin.
SorafenibThe metabolism of Lorcaserin can be decreased when combined with Sorafenib.
SparteineThe metabolism of Sparteine can be decreased when combined with Lorcaserin.
St. John's WortThe serum concentration of Lorcaserin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Lorcaserin can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Lorcaserin can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Lorcaserin.
TadalafilThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Tadalafil.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Lorcaserin.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Lorcaserin.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Lorcaserin.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Lorcaserin.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Lorcaserin.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Lorcaserin.
TelaprevirThe metabolism of Lorcaserin can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Lorcaserin can be decreased when combined with Telithromycin.
TenofovirThe metabolism of Lorcaserin can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Lorcaserin can be decreased when combined with Terbinafine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Lorcaserin.
TeriflunomideThe serum concentration of Lorcaserin can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Lorcaserin.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Lorcaserin.
TheophyllineThe metabolism of Lorcaserin can be decreased when combined with Theophylline.
ThioproperazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Thioridazine.
ThioridazineThe metabolism of Lorcaserin can be decreased when combined with Thioridazine.
ThiotepaThe metabolism of Lorcaserin can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Thiothixene.
TiclopidineThe metabolism of Lorcaserin can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Lorcaserin.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Lorcaserin.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Lorcaserin.
TocilizumabThe serum concentration of Lorcaserin can be decreased when it is combined with Tocilizumab.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Lorcaserin.
TopiramateThe metabolism of Lorcaserin can be decreased when combined with Topiramate.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Lorcaserin.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lorcaserin.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lorcaserin.
TranylcypromineThe metabolism of Lorcaserin can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Tranylcypromine.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Lorcaserin.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Lorcaserin.
TrifluoperazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Triflupromazine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Lorcaserin.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lorcaserin.
UdenafilThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Udenafil.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Lorcaserin.
VardenafilThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Vardenafil.
VemurafenibThe serum concentration of Lorcaserin can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Lorcaserin can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Lorcaserin can be decreased when combined with Verapamil.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Lorcaserin.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Lorcaserin.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Lorcaserin.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Lorcaserin.
VoriconazoleThe metabolism of Lorcaserin can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Lorcaserin.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lorcaserin.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Lorcaserin.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Lorcaserin.
ZiprasidoneThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ziprasidone.
ZiprasidoneThe metabolism of Lorcaserin can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lorcaserin.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Lorcaserin.
ZotepineThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Zuclopenthixol.
Food Interactions
  • Administration with or without food has no effect.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Halford JC: Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006 Apr;7(4):312-8. [PubMed:16625817 ]
  2. Jandacek RJ: APD-356 (Arena). Curr Opin Investig Drugs. 2005 Oct;6(10):1051-6. [PubMed:16259227 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Nadp binding
Specific Function:
This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. Form I catalyzes the N-oxygenation of secondary and tertiary amines.
Gene Name:
FMO1
Uniprot ID:
Q01740
Molecular Weight:
60310.285 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Usmani KA, Chen WG, Sadeque AJ: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20. [PubMed:22266842 ]
Comments
comments powered by Disqus
Drug created on October 20, 2007 04:39 / Updated on September 29, 2016 02:27